DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

HUM·Humana Inc.

$.
-. (-.%)
High
$306.45
Open
$305.60
Market Cap
36.97B
52W High
$315.66
Low
$302.89
P. Close
$307.95
P/E
32.72
52W Low
$163.11
Fwd P/E
19.89
Mean Target
-
Technical Score (1D)
100
BUY
News Sentiment
47
MIXED
Humana's stock saw a significant price target increase from Barclays, moving to $344 from $180, though the firm maintained an Equalweight rating. This optimistic valuation adjustment comes as Humana experienced a decline due to Medicare Advantage rates falling short of expectations. The company's current average analyst rating remains a 'hold' with a consensus target of $266.17. Broader market sentiment has favored momentum stocks, creating headwinds for quality-focused investments like Humana, while increased volatility from AI and geopolitical events has also contributed to market declines. Investors will be watching for any further commentary from Barclays regarding their revised outlook and how Humana navigates the Medicare Advantage rate environment.
Earnings Summary
Humana Inc. is a U.S.-based healthcare company specializing in medical and specialty insurance products, operating through its Insurance and CenterWell segments. The company offers a wide array of health plans, including medical, supplemental, and prescription drug coverage, serving individuals, employer groups, and government programs like Medicare and Medicaid. Humana's integrated services, such as pharmacy benefit management and primary care centers, aim to provide a comprehensive approach to healthcare delivery. In its most recent reported quarters, Humana experienced mixed earnings performance. For Q1 2026, the company reported an Earnings Per Share (EPS) of $10.31, exceeding the estimated $10.16, and revenue reached $39.65 billion, surpassing the estimate of $39.39 billion. This followed a challenging Q4 2025, where EPS was a loss of $3.96 against an estimate of $10.57, and revenue of $32.64 billion missed the estimate of $35.51 billion. Prior to that, Q3 2025 saw EPS of $3.24, beating the estimate of $2.83, and Q2 2025 reported EPS of $6.27, also exceeding the estimate of $5.87. This pattern indicates a recent trend of beating EPS estimates in Q2 and Q3 2025, followed by a significant miss in Q4 2025, and a return to beating estimates in Q1 2026, alongside revenue beats in the most recent two quarters. Historically, Humana's year-over-year growth trajectory has shown variability, with notable beats in EPS in Q1 and Q2 2025, contrasting with a substantial miss in Q4 2025. The company has demonstrated a pattern of revenue growth, even in quarters with EPS challenges. Recent news highlights significant analyst upgrades, with Deutsche Bank raising its rating to 'Buy' and price target to $441, citing expectations of a recovery in Medicare star ratings and a stabilization in the managed care market for 2026. UBS also raised its price target to $320. These upgrades are partly driven by Humana's expanded Medicare Advantage coverage for CVRx's Barostim therapy. Investors will be watching for continued positive momentum in Medicare star ratings and the impact of expanded coverage on financial performance in upcoming quarters, alongside management's commentary on operational costs and leverage.

EPS

EstBeatMiss
$-6.29$-1.24$3.81$8.86$13.91Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.78 - -
Q1'26$10.16$10.31+1.5%
Q4'25$10.57$-3.96-137.5%
Q3'25$2.83$3.24+14.6%
Q2'25$5.87$6.27+6.9%
Q1'25$10.07$11.58+15.0%

Revenue

EstBeatMiss
$30.8B$33.7B$36.5B$39.4B$42.3BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$41.0B - -
Q1'26$39.4B$39.6B+0.7%
Q4'25$35.5B$32.6B-8.1%
Q3'25 - $32.6B -
Q2'25 - $32.4B -
Q1'25 - $32.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

HUM Stock Snapshot

HUM is currently trading at $303.97, giving Humana Inc. a market cap of 36.97B and a P/E ratio of 32.7. Today's range spans $302.89–$306.45, with shares opening at $305.60 and moving down $3.98 (1.3%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 47/100.

Over the past year HUM has traded between $163.11 and $315.66 - the current price is +86.4% off the 52-week low and -3.7% from the high.

The BUY technical setup for HUM (100/100) is worth attention in the context of the broader Healthcare sector. At $303.97 (near 52-week highs), with 36.97B in capitalization and neutral sentiment at 47/100 The current P/E ratio stands at 32.7., this large-cap name sits at the intersection where momentum strategies and fundamental growth investors both find something to like. Annual range: $163.11–$315.66.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (100/100) and news sentiment (47/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $303.97 (near 52-week highs), HUM's position within the $163.11–$315.66 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…